中国临床药理学与治疗学2009，Vol.14Issue(6)：670-676,7.
MDR1基因C3435T多态性对替米沙坦稳态血药浓度及降压疗效的影响
Effects of MDR1 gene C3435T polymorphism on the steady-state plasma concentration and hypotensive activity of telmisartan
范秀珍 1郭歆 2王华杰 1程泽能2
作者信息
- 1. 湖南省邵阳市第一人民医院药剂科,邵阳,422000,湖南
- 2. 中南大学药学院,长沙,410013,湖南
- 折叠
摘要
Abstract
AIM: To study the effects of MDR1 C3435T polymorphism on steady-state plasma concentration and hypotensive activity of telmisartan. METHODS: 61 cases of essential hypertension patients were received oral dose of 40 mg telmisartan per day for 30 days. The genotyping of the MDR1 C3435T polymorphism in the patients was performed by using method of polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The plasma concentrations of telmisartan were determined by high performance liquid chromatograpy-Fluorescence detector (HPLC-FLD). The blood pressures of the patients were measured before and after treatment. The plasma concentrations and therapeutic effect of telmisartan were compared among the three different genotype groups. RESULTS: Among the 61 cases of elderly hypertension patients, the frequencies of 3435CC, 3435TT and 3435CT were 39.34%, 11.48% and 49.18%, respectively. There were no differences between healthy people and the hypertension patients in allele frequencies of MDR1 C3435T. The telmisartan steady-state concentration and curative effect also had no significant differences among the three genotype groups in the hypertensive patients. CONCLUSION: The MDR1 C3435T polymorphism does not affect the steady-state plasma concentrate and curative effect of telmisartan in hypertension patients.关键词
多药耐药基因/P-糖蛋白/单核苷酸多态性/替米沙坦/稳态血药浓度Key words
multidrug resistance gene/ P-glycoprotein/ single nucleotide polymorphisms/ telmisartan/ steady-state plasma concentration分类
医药卫生引用本文复制引用
范秀珍,郭歆,王华杰,程泽能..MDR1基因C3435T多态性对替米沙坦稳态血药浓度及降压疗效的影响[J].中国临床药理学与治疗学,2009,14(6):670-676,7.
